Profile data is unavailable for this security.
About the company
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
- Revenue in USD (TTM)198.96m
- Net income in USD-11.94m
- Incorporated1991
- Employees414.00
- LocationMannKind Corp1 Casper StreetDANBURY 06810United StatesUSA
- Phone+1 (818) 661-5000
- Fax+1 (302) 636-5454
- Websitehttps://mannkindcorp.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mirum Pharmaceuticals Inc | 186.37m | -163.42m | 1.18bn | 264.00 | -- | 4.72 | -- | 6.34 | -4.08 | -4.08 | 4.56 | 5.32 | 0.3729 | 3.37 | 4.05 | 705,962.10 | -32.70 | -38.93 | -38.55 | -44.88 | 74.76 | -- | -87.68 | -190.71 | 4.19 | -79.67 | 0.552 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
Belite Bio Inc (ADR) | 0.00 | -31.63m | 1.19bn | 20.00 | -- | 12.87 | -- | -- | -1.24 | -1.24 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -45.54 | -- | -47.50 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
Scholar Rock Holding Corp | 0.00 | -165.79m | 1.20bn | 150.00 | -- | 5.21 | -- | -- | -1.99 | -1.99 | 0.00 | 2.96 | 0.00 | -- | -- | 0.00 | -49.55 | -38.14 | -55.26 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.1817 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
Pharvaris NV | 0.00 | -116.19m | 1.22bn | 65.00 | -- | 5.81 | -- | -- | -3.18 | -3.18 | 0.00 | 4.04 | 0.00 | -- | -- | 0.00 | -57.65 | -- | -63.41 | -- | -- | -- | -- | -- | -- | -6.96 | 0.0019 | -- | -- | -- | -78.64 | -- | -- | -- |
Deciphera Pharmaceuticals Inc | 163.36m | -194.94m | 1.23bn | 355.00 | -- | 3.48 | -- | 7.51 | -2.29 | -2.29 | 1.92 | 4.36 | 0.3522 | 0.1787 | 6.01 | 460,157.80 | -42.03 | -44.54 | -52.63 | -52.24 | 97.72 | -- | -119.34 | -245.88 | 3.59 | -- | 0.00 | -- | 21.87 | -- | -8.95 | -- | -7.11 | -- |
MannKind Corp | 198.96m | -11.94m | 1.25bn | 414.00 | -- | -- | -- | 6.29 | -0.0464 | -0.0464 | 0.7087 | -0.9116 | 0.5165 | 2.50 | 12.55 | 480,584.50 | -3.10 | -26.07 | -3.99 | -37.80 | 68.45 | 59.68 | -6.00 | -57.61 | 3.31 | 0.5023 | 1.90 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
Ligand Pharmaceuticals Inc | 131.31m | 53.82m | 1.26bn | 58.00 | 24.52 | 1.79 | 13.97 | 9.61 | 2.91 | 2.81 | 7.26 | 39.92 | 0.1695 | 0.5642 | 4.15 | 2,264,035.00 | 6.94 | 12.32 | 7.50 | 12.99 | 91.99 | 81.65 | 40.98 | 80.32 | 12.72 | -- | 0.00001 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
Tarsus Pharmaceuticals Inc | 17.45m | -135.89m | 1.30bn | 244.00 | -- | 6.00 | -- | 74.29 | -4.58 | -4.58 | 0.5939 | 5.76 | 0.0707 | -- | 1.64 | 71,504.10 | -55.09 | -31.56 | -61.63 | -33.82 | 90.87 | -- | -778.89 | -242.59 | 6.85 | -- | 0.1315 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
Collegium Pharmaceutical Inc | 566.77m | 48.16m | 1.31bn | 197.00 | 46.37 | 6.67 | 6.62 | 2.31 | 0.8823 | 0.8823 | 12.53 | 6.13 | 0.4891 | 6.10 | 3.13 | 2,876,990.00 | 4.16 | 2.79 | 6.75 | 4.80 | 57.55 | 50.88 | 8.50 | 5.16 | 1.10 | 2.59 | 0.7734 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
AbCellera Biologics Inc | 38.03m | -146.40m | 1.31bn | 586.00 | -- | 1.13 | -- | 34.57 | -0.5062 | -0.5062 | 0.1315 | 3.96 | 0.0251 | -- | 1.10 | 64,890.79 | -9.67 | 6.08 | -10.49 | 6.67 | -- | -- | -384.99 | 24.69 | 7.32 | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
Gyre Therapeutics Inc | 0.00 | -44.24m | 1.34bn | 7.00 | -- | -- | -- | -- | -20.60 | -20.60 | 0.00 | 1.39 | 0.00 | -- | -- | 0.00 | -215.90 | -58.25 | -235.61 | -72.12 | -- | -- | -- | -817.06 | -- | -- | 0.00 | -- | -89.18 | -4.85 | 90.63 | -- | -- | -- |
Ironwood Pharmaceuticals, Inc. | 442.74m | -1.00bn | 1.35bn | 267.00 | -- | -- | -- | 3.05 | -6.51 | -6.51 | 2.59 | -2.21 | 0.5634 | -- | 3.62 | 1,658,184.00 | -131.28 | -4.54 | -162.45 | -5.20 | -- | -- | -233.00 | -7.81 | -- | 63.79 | 1.98 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
Pacira Biosciences Inc | 674.98m | 41.96m | 1.35bn | 711.00 | 42.78 | 1.55 | 11.48 | 2.00 | 0.6789 | 0.6789 | 12.33 | 18.72 | 0.4147 | 1.84 | 6.62 | 949,336.10 | 2.58 | 3.35 | 2.79 | 3.98 | 72.64 | 72.63 | 6.22 | 8.57 | 4.17 | 9.85 | 0.3752 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
Prothena Corporation PLC | 91.37m | -147.03m | 1.35bn | 173.00 | -- | 2.41 | -- | 14.79 | -2.80 | -2.80 | 1.68 | 10.46 | 0.1256 | -- | -- | 528,150.30 | -20.22 | -14.20 | -21.82 | -15.11 | -- | -- | -160.92 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
Spyre Therapeutics Inc | 886.00k | -338.79m | 1.35bn | 30.00 | -- | -- | -- | 1,528.43 | -75.04 | -75.04 | 0.1285 | 7.45 | 0.0043 | -- | 4.73 | 29,533.33 | -164.06 | -101.87 | -184.94 | -118.83 | -- | -- | -38,238.15 | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Dec 2023 | 20.19m | 7.47% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 14.58m | 5.39% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 12.94m | 4.79% |
Nitorum Capital LPas of 31 Dec 2023 | 10.83m | 4.01% |
Avoro Capital Advisor LLCas of 31 Dec 2023 | 9.00m | 3.33% |
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 5.94m | 2.20% |
Geode Capital Management LLCas of 31 Dec 2023 | 5.84m | 2.16% |
D. E. Shaw & Co. LPas of 31 Dec 2023 | 2.99m | 1.11% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 2.55m | 0.94% |
Parkman Healthcare Partners LLCas of 31 Dec 2023 | 2.50m | 0.92% |